Statute Details
- Title: National Registry of Diseases (Acute Myocardial Infarction Notification) Regulations 2012
- Act Code: NRDA2007-S410-2012
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: National Registry of Diseases Act (Cap. 201B)
- Enacting Formula / Power Source: Made under sections 6, 7 and 23 of the National Registry of Diseases Act
- Commencement: 1 September 2012
- Key Provisions: Regulation 1 (citation and commencement); Regulation 2 (definitions); Regulation 3 (form, time and manner of notification); Regulation 4 (collection of additional information)
- Schedules: First Schedule (information to be submitted); Second Schedule (forms/listings); Third Schedule (additional information)
- Status: Current version as at 27 March 2026 (per provided extract)
What Is This Legislation About?
The National Registry of Diseases (Acute Myocardial Infarction Notification) Regulations 2012 (“AMIN Notification Regulations”) create a legal framework requiring healthcare institutions in Singapore to notify the Registrar of the National Registry of Diseases when a patient has been diagnosed with, or is undergoing treatment for, acute myocardial infarction (“AMI”). In plain language, the Regulations ensure that AMI cases are systematically reported to a central registry so that public health authorities can monitor disease incidence and outcomes.
The Regulations sit under the broader National Registry of Diseases Act (Cap. 201B). The Act provides the overarching authority for establishing and maintaining the registry and for requiring notifications. These Regulations specify the operational details: what counts as AMI, what information must be submitted, which notification forms must be used, when notifications must be made, and how the Registrar may request further information after receiving an initial notification.
Practically, the Regulations are aimed at improving data completeness and timeliness. They also recognise that AMI can arise in different clinical contexts, including as a complication of cardiovascular interventions. By defining AMI in terms of clinical and diagnostic indicators, the Regulations reduce ambiguity and support consistent reporting across healthcare institutions.
What Are the Key Provisions?
1. Citation and commencement (Regulation 1)
Regulation 1 provides that the Regulations may be cited as the National Registry of Diseases (Acute Myocardial Infarction Notification) Regulations 2012 and that they came into operation on 1 September 2012. For practitioners, this matters because the Regulations include specific transitional timing rules for patients whose AMI treatment commenced before that date.
2. Definitions—what counts as “acute myocardial infarction” (Regulation 2)
Regulation 2 defines “acute myocardial infarction” by reference to a set of diagnostic criteria. The definition includes myocardial infarction where one or more of the following are present:
- Changes in cardiac biomarkers beyond typical limits for the particular test, together with either:
- symptoms indicative of myocardial ischaemia; or
- electrocardiogram (ECG) changes indicative of new myocardial ischaemia.
- Development of new pathological Q waves in the patient’s ECG.
- New loss of viable myocardium or new regional wall motion abnormality.
- Fresh thrombus.
The definition also expressly includes AMI developed as a complication of cardiovascular intervention for some other cardiac condition. This is important for hospitals and clinicians because it expands the reporting trigger beyond “spontaneous” AMI to include procedure-related AMI.
Regulation 2 also defines “patient” as a person to whom a notification under Regulation 3 relates. While seemingly simple, this definition anchors the scope of who is covered by the notification and subsequent requests for additional information.
3. Form, time and manner of notification (Regulation 3)
Regulation 3 is the core compliance provision. It addresses notifications “for the purposes of section 6(1) of the Act” and specifies that a notification by the manager of a healthcare institution to the Registrar must be made when a person has been diagnosed with, or is undergoing treatment for, AMI at that institution.
(a) Content requirements—First Schedule
The notification must contain the information specified in the First Schedule. This means the legal obligation is not satisfied by a bare clinical statement; the institution must provide the prescribed dataset.
(b) Prescribed format—Second Schedule
The notification must be made in the appropriate Form or Listing specified in the Second Schedule. The extract indicates that these forms/listings may be downloaded from the Registry’s internet website or obtained from the Registry office. For legal and compliance teams, this is a reminder that “substance” alone is insufficient—format and listing selection are part of the statutory method.
(c) Approved delivery methods
The notification must be sent to the Registrar by one of the following methods:
- by hand (including by courier);
- by registered mail; or
- by using a secure electronic notification system approved by the Registrar.
This provision is significant for operational compliance. It implies that institutions should ensure they have access to the approved secure electronic system (if they intend to use it) and that internal processes can meet the required delivery standards.
(d) Timing—three distinct deadlines
Regulation 3 sets out when the notification must be made, depending on the patient’s clinical timeline:
- Where the patient has been diagnosed with AMI: not later than 3 months after the diagnosis was first made.
- Transitional rule (treatment commenced before 1 September 2012 and continues on/after that date): not later than 30 November 2012.
- Where treatment commenced on or after 1 September 2012: not later than 3 months after the treatment commenced.
These deadlines are central for practitioners advising hospitals on compliance risk. They also create a practical distinction between “diagnosis date” and “treatment commencement date.” Where both exist, institutions must be able to identify which date triggers the relevant deadline.
4. Collection of additional information (Regulation 4)
After receiving a notification under Regulation 3, the Registrar or an authorised Registry officer may require the manager of the healthcare institution to provide all or any of the additional information specified in the Third Schedule concerning the patient.
Regulation 4 therefore creates a two-stage reporting obligation: an initial notification with First Schedule information, followed by potential follow-up requests for additional data. From a legal standpoint, this matters because compliance is not limited to the first submission; institutions must be prepared to respond to further information requests under section 7(1) of the Act.
How Is This Legislation Structured?
The Regulations are structured in a straightforward manner:
- Regulations 1–2 set out the citation/commencement and define key terms (notably “acute myocardial infarction”).
- Regulation 3 provides the operational requirements for notification: required content (First Schedule), required form/listing (Second Schedule), approved delivery methods, and timing rules.
- Regulation 4 addresses post-notification data collection by empowering the Registrar to request additional information (Third Schedule).
- Schedules support the substantive obligations:
- First Schedule: Information to be submitted with the notification.
- Second Schedule: Forms of notification (and/or listings) to be used.
- Third Schedule: Additional information that may be requested after initial notification.
For practitioners, the schedules are not merely administrative appendices; they are integral to what the law requires. Even though the extract does not reproduce the schedule contents, the Regulations make clear that compliance depends on those specified datasets and forms.
Who Does This Legislation Apply To?
The notification duty is imposed on the manager of a healthcare institution that has diagnosed or is treating a patient with AMI. While the Regulations use the term “manager,” in practice this typically means the institution’s authorised responsible officer or management role tasked with regulatory reporting.
The obligation is triggered when AMI occurs at the healthcare institution—either because the patient is diagnosed there or because the patient is undergoing treatment there. The definition of AMI includes multiple diagnostic modalities and also covers procedure-related AMI, so institutions must consider whether their clinical pathways and diagnostic documentation capture the full range of cases that meet the statutory definition.
Why Is This Legislation Important?
From a compliance and risk perspective, these Regulations translate the National Registry of Diseases Act’s general notification framework into specific, enforceable operational duties. The key practical impact is that hospitals must implement processes to identify AMI cases, determine the correct trigger date (diagnosis vs treatment commencement), compile the First Schedule information, select the correct Second Schedule form/listing, and submit within the statutory deadlines.
For legal practitioners advising healthcare providers, the Regulations also highlight that reporting is not a one-off event. Regulation 4 allows the Registrar to request additional information under the Third Schedule. This means institutions should maintain adequate records and be able to respond promptly to follow-up requests without compromising patient confidentiality obligations under applicable data protection and medical confidentiality frameworks.
Finally, the Regulations are important for public health governance. Accurate and timely AMI reporting supports surveillance, research, and policy planning. The statutory definition of AMI and the prescribed notification mechanics aim to improve data consistency across institutions, which in turn strengthens the reliability of registry outputs.
Related Legislation
- National Registry of Diseases Act (Cap. 201B) — the enabling Act providing the legal basis for notifications and the Registrar’s powers (including sections 6, 7 and 23 referenced in the enacting formula).
- Diseases Act — referenced in the provided metadata as “Timeline / Authorising Act” (note: the extract indicates the enabling Act is the National Registry of Diseases Act; practitioners should confirm the precise legislative chain in the official consolidated legislation view).
Source Documents
This article provides an overview of the National Registry of Diseases (Acute Myocardial Infarction Notification) Regulations 2012 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.